natgillin/translations-raw huggingface dataset:
It is recommended to start cetuximab therapy one week before radiation therapy and to continue cetuximab therapy until the end of the radiation therapy period. 
Priporoča se, da se zdravljenje s cetuksimabom začne en teden pred radioterapijo in da se nadaljuje do konca obdobja radioterapije.
Please also read 'Side effects concerning the skin' in section 4 for details, as some skin reactions may have serious consequences for you, including life-threatening conditions. 
Za podrobnosti preberite tudi poglavje 4 "Neželeni učinki, povezani s kožo", saj imajo lahko nekatere kožne reakcije za vas hude posledice, vključno take, ki so lahko smrtno nevarne.
In vitro cetuximab inhibits the production of angiogenic factors by tumour cells and blocks endothelial cell migration. 
In vitro cetuksimab zavira tvorbo angiogenih faktorjev v tumorskih celicah in blokira migracijo endotelijskih celic.
CRS is normally most severe in relation to the first infusion. 
Sindrom sproščanja citokinov je običajno najbolj resen v povezavi s prvim infundiranjem.
Intravenous infusions of cetuximab exhibited dose-dependent pharmacokinetics at weekly doses ranging from 5 to 500 mg/m body surface area. 
Pri intravenskem infundiranju cetuksimaba so ugotavljali od odmerka odvisno farmakokinetiko s tedenskimi odmerki od 5 do 500 mg/m² telesne površine.
Determination of serum electrolyte levels is recommended prior to and periodically during cetuximab treatment. 
Priporoča se določanje koncentracije elektrolitov v serumu pred zdravljenjem in periodično med zdravljenjem s cetuksimabom.
Severe infusion-related reactions, including anaphylactic reactions, may commonly occur, in some cases with fatal outcome. 
Pogosto se lahko pojavijo hude reakcije, povezane z infundiranjem, vključno z anafilaktičnimi, v nekaterih primerih s smrtnim izidom.
No clinical benefit could be demonstrated in patients with KPS ≤ 80 who were 65 years of age or older. 
Klinične koristi ni bilo možno pokazati pri bolnikih, ki so imeli KPS ≤ 80 in so bili stari ≥ 65.
Main side effects concerning the skin include: 
Glavni neželeni učinki, povezani s kožo, so:
Mutational status should be determined by an experienced laboratory using validated test methods for detection of KRAS and NRAS (exons 2, 3, and 4) mutations (see section 4.4 and 5.1). 
Mutacijski status mora ugotoviti izkušen laboratorij z uporabo validiranih testnih metod za detekcijo mutacij genov KRAS in NRAS (eksoni 2, 3 in 4).
They generally resolve, without sequelae, over time following cessation of treatment if the recommended adjustments in dose regimen are followed (see section 4.4). 
Navadno po koncu zdravljenja sčasoma izginejo brez posledic, če upoštevate priporočeno prilagoditev odmerjanja (glejte poglavje 4.4).
Cetuximab plus FOLFIRI 
Cetuximab in FOLFIRI
An integrated analysis across all clinical studies showed that the pharmacokinetic characteristics of cetuximab are not influenced by race, age, gender, renal or hepatic status. 
Integrirana analiza vseh kliničnih študij je pokazala, da rasa, starost, spol ter delovanje ledvic ali jeter ne vplivajo na farmakokinetične značilnosti cetuksimaba.
They normally occur during the infusion, within 1 hour afterwards, or sometimes also after this period. 
Navadno se pojavijo med infundiranjem, eno uro po njem, včasih pa tudi pozneje.
If interstitial lung disease is diagnosed, cetuximab must be discontinued and the patient be treated appropriately. 
Če ugotovite intersticijsko bolezen pljuč, morate zdravljenje s cetuksimabom prekiniti, in bolnika ustrezno zdraviti.
• For administration with infusion pump or gravity drip (undiluted): Calculate the required volume of Erbitux. 
• Za uporabo z infuzijsko črpalko ali težnostno kapalno infuzijo (nerazredčeno): Izračunajte potrebni volumen zdravila Erbitux.
In a study of cetuximab administered in combination with irinotecan, the mean cetuximab trough levels were 50.0 microgram per mL in week 12 and 49.4 microgram per mL in week 36. 
V študiji kombinirane terapije s cetuksimabom in irinotekanom je bila srednja najmanjša koncentracija 50,0 mikrograma/ml v 12. tednu in 49,4 mikrograma/ml v 36. tednu.
Cetuximab in combination with radiation therapy for locally advanced disease 
Cetuksimab v kombinaciji z radioterapijo za lokalno napredovalo bolezen
Frequency not known:Superinfection of skin lesions*. 
superinfekcija kožnih lezij*.
Only in study EMR 62 202-007, a post-hoc analysis was not possible. 
Post-hoc analiza ni bila mogoča samo v študiji EMR 62 202-007.
In the KRAS wild-type population of the CALGB/SWOG 80405 study (n=1137), superiority of cetuximab plus chemotherapy over bevacizumab plus chemotherapy was not shown based on an interim analysis. 
Za populacijo nemutiranega tipa KRAS v študiji CALGB/SWOG 80405 (n = 1.137) na podlagi vmesne analize ni bila dokazana superiornost cetuksimaba in kemoterapije pred bevacizumabom in kemoterapijo.
Side effects in combination with other anticancer treatments 
Neželeni učinki pri kombinaciji z drugimi oblikami zdravljenja proti raku
This may lead to infectious complications including life-threatening conditions, especially if you experience skin reactions, inflammation of the lining of the intestine and mouth or diarrhoea. 
To lahko povzroči zaplete zaradi okužb, vključno s smrtno nevarnimi boleznimi, še posebej, če se pojavijo kožne reakcije, vnetje črevesja in ustne sluznice ali driska.
Skin lesions induced by cetuximab may predispose patients to superinfections (e.g. with S. aureus), which may lead to subsequent complications, e.g. cellulitis, erysipelas, or, potentially with fatal outcome, staphylococcal scalded skin syndrome, necrotising fasciitis or sepsis. 
Kožne razjede, ki jih povzroča cetuksimab, so lahko vzrok za pojav superinfekcij (npr. z bakterijo S. aureus), ki lahko povzročijo zaplete, kot so celulitis, erizipel ali, potencialno s smrtnim izidom, stafilokokni sindrom luščenja kože, nekrotizirajoči fasciitis ali sepso.
In combination with platinum-based chemotherapy, the frequency of severe leukopenia or severe neutropenia may be increased, and thus may lead to a higher rate of infectious complications such as febrile neutropenia, pneumonia and sepsis compared to platinum-based chemotherapy alone (see section 4.4). 
V kombinaciji s kemoterapijo na osnovi platine se lahko pogostnost hude levkopenije ali hude nevtropenije poveča, kar lahko poveča pogostnost zapletov zaradi okužb, kot je febrilna nevtropenija, pljučnica ali sepsa, v primerjavi s kemoterapijo na osnovi platine brez cetuksimaba (glejte poglavje 4.4).
When cetuximab is used in combination with chemotherapeutic agents, also refer to their respective product information. 
Kadar se cetuksimab uporablja v kombinaciji s kemoterapevtiki, glejte tudi zadevne informacije o zdravilu.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 100 mg/20 mL 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 100 mg/20 ml
• decrease in blood levels of magnesium 
• zmanjšana raven magnezija v krvi
Study data demonstrate that patients with metastatic colorectal cancer and activating RAS mutations are highly unlikely to benefit from treatment with cetuximab or a combination of cetuximab and chemotherapy and as add-on to FOLFOX4 a significant negative effect on progression-free survival time (PFS) was shown. 
Podatki iz študije so pokazali, da je malo verjetno, da bi bolnikom z metastatskim kolorektalnim rakom in z aktivacijskimi mutacijami RAS zdravljenje s cetuksimabom ali kombinacijo cetuksimaba in kemoterapije koristilo, v primeru, da je šlo za dodatno zdravilo k FOLFOX4, pa so se pokazali pomembni negativni učinki na čas preživetja brez napredovanja bolezni (PFS).
Erbitux 5 mg/mL solution for infusion is supplied in vials containing 20 mL or 100 mL. 
Erbitux 5 mg/ml raztopina za infundiranje je na voljo v vialah z 20 ml ali 100 ml raztopine.
Erbitux must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products. 
Infundiranje zdravila Erbitux mora potekati pod nadzorom zdravnika, ki ima izkušnje z uporabo zdravil z delovanjem na novotvorbe.
Cetuximab serum concentrations reached stable levels after three weeks of cetuximab monotherapy. 
Serumske koncentracije cetuksimaba so dosegle stalno raven po treh tednih monoterapije s cetuksimabom.
In addition, cetuximab was investigated in combination with chemotherapy in an investigator-initiated randomised controlled phase-III study (COIN, COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy). 
Poleg tega so cetuksimab raziskovali v kombinaciji s kemoterapijo v randomizirani kontrolirani študiji 3. faze na pobudo raziskovalca (stalna kemoterapija s cetuksimabom ali občasno kemoterapijoCOIN (COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy)).
Of these, 362 patients received cetuximab and oxaliplatin plus fluoropyrimidines (117 patients OxMdG and 245 patients XELOX) and 367 patients received oxaliplatin plus fluoropyrimidines alone (127 patients OxMdG and 240 patients XELOX). 
Med njimi je 362 bolnikov prejelo cetuksimab in oksaliplatin ter fluoropirimidin (117 bolnikov OxMdG in 245 bolnikov XELOX), 367 bolnikov je prejelo samo oksaliplatin in fluoropirimidin (127 bolnikov OxMdG in 240 bolnikov XELOX).
In a randomised controlled clinical study with 424 patients, reporting rates of severe acute radiation dermatitis and mucositis as well as of late radiation-therapy-related events were slightly higher in patients receiving radiation therapy in combination with cetuximab than in those receiving radiation therapy alone. 
V randomizirani, nadzorovani klinični študiji, v kateri je sodelovalo 424 bolnikov, je bila pogostnost hudega akutnega radiacijskega dermatitisa in mukozitisa ter tudi zakasnelih neželenih učinkov, povezanih z radioterapijo, o katerih so poročali, nekoliko večja pri bolnikih, ki so prejemali radioterapijo v kombinaciji s cetuksimabom, kot pri bolnikih, ki so prejemali radioterapijo v monoterapiji.
MARKETING AUTHORISATION NUMBER(S) EU/1/04/281/003 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/04/281/003
When cetuximab was administered at an initial dose of 400 mg/m 2 body surface area, the mean volume of distribution was approximately equivalent to the vascular space (2.9 L/m 2 with a range of 
Ko so cetuksimab dajali v začetnem odmerku 400 mg/m² telesne površine, je bil srednji porazdelitveni volumen približno enak znotrajžilnemu prostoru (2,9 l/m², razpon od 1,5 do 6,2 l/m²).
What Erbitux looks like and contents of the pack 
Izgled zdravila Erbitux in vsebina pakiranja
• For administration with a syringe pump: Calculate the required volume of Erbitux. 
• Za uporabo s črpalko za brizgo: Izračunajte potreben volumen zdravila Erbitux.
Transfer the Erbitux into a sterile evacuated container or bag. 
Prenesite zdravilo Erbitux v sterilen prazen vsebnik ali vrečo.
For the dosage or recommended dose modifications of concomitantly used chemotherapeutic agents, refer to the product information for these medicinal products. 
Za odmerjanje ali priporočene spremembe odmerka sočasno uporabljenih kemoterapevtikov glejte informacije za ta zdravila.
They must not be administered earlier than 1 hour after the end of the cetuximab infusion. 
Ne smejo se dati prej kot 1 uro po koncu infuzije cetuksimaba.
In both in vitro and in vivo assays, cetuximab inhibits the proliferation and induces apoptosis of human tumour cells that express EGFR. 
Tako v in vitro kot v in vivo testih cetuksimab zavira proliferacijo in inducira apoptozo človeških tumorskih celic z ekspresijo EGFR.
In these patients, Erbitux is used alone or in combination with other anticancer medicines. 
Pri teh bolnikih se zdravilo Erbitux uporablja samostojno ali skupaj z drugimi zdravili proti raku.
In the overall population, irrespective of KRAS status, the results reported for cetuximab plus irinotecan (648 patients) vs. irinotecan alone (650 patients) were: median overall survival time (OS) 10.71 vs. 9.99 months (HR 0.98), median progression free survival time (PFS) 4.0 vs. 2.6 months (HR 0.69), and objective response rate (ORR) 16.4% vs. 4.2%. 
Pri celokupni populaciji ne glede na status KRAS so bili rezultati, o katerih so poročali za cetuksimab in irinotekan (648 bolnikov) v primerjavi s samo irinotekanom (650 bolnikov) naslednji: mediana celokupnega preživetja (OS) 10,71 v primerjavi z 9,99 meseci (razmerje tveganja 0,98), mediana časa preživetja brez napredovanja bolezni (PFS) 4,0 v primerjavi z
Special attention is recommended for patients with reduced performance status and pre-existing cardiopulmonary disease. 
Pri bolnikih z zmanjšanim indeksom zmogljivosti in pri tistih z obstoječo srčno-pljučno boleznijo je priporočljiva posebna pozornost.
It is recommended that cetuximab treatment be continued until progression of the underlying disease. 
Priporočljivo je, da z zdravljenjem s cetuksimabom nadaljujete do napredovanja osnovne bolezni.
Mild or moderate infusion-related side effects include: 
Blagi ali zmerni neželeni učinki, povezani z infundiranjem, so:
Cetuximab in combination with platinum-based chemotherapy in recurrent and/or metastatic disease 
Cetuksimab v kombinaciji s kemoterapijo na osnovi platine pri ponavljajoči se in/ali metastatski bolezni
Repeat this procedure until the calculated volume has been infused. 
Ponavljajte ta postopek, dokler ne bo infundiran ves izračunani volumen.
In combination with fluoropyrimidines, the frequency of cardiac ischaemia including myocardial infarction and congestive heart failure as well as the frequency of hand-foot syndrome (palmar-plantar erythrodysaesthesia) were increased compared to that with fluoropyrimidines. 
Pri kombinaciji s fluoropirimidini se je v primerjavi z uporabo fluoropirimidinov, kot monoterapije, povečala pogostnost srčne ishemije, vključno z miokardnim infarktom in kongestivno srčno odpovedjo ter pogostnost sindroma dlani in stopal (palmarno-plantarna eritrodisestezija).
Of the KRAS mutant population, 297 patients received cetuximab and oxaliplatin plus fluoropyrimidines (101 patients OxMdG and 196 patients XELOX) and 268 patients received oxaliplatin plus fluoropyrimidines alone (78 patients OxMdG and 190 patients XELOX). 
Med populacijo z mutiranim genom KRAS je 297 bolnikov prejelo cetuksimab in oksaliplatin in fluoropirimidin (101 bolnik OxMdG in 196 bolnikov XELOX), 268 bolnikov je prejelo samo oksaliplatin in fluoropirimidin (78 bolnikov OxMdG in 190 bolnikov XELOX).
RAS status was evaluable in tumour samples of 407 KRAS exon 2 wild-type patients reflecting 69% of the overall KRAS exon 2 wild-type patient population (592 patients). 
Status RAS so ocenili na vzorcih tumorja pri 407 bolnikih z nemutiranim tipom KRAS (eksona 2), kar predstavlja 69 % celokupne populacije bolnikov z nemutiranim tipom KRAS eksona 2 (592 bolnikov).
• skin reactions typical for radiation therapy 
• kožne reakcije, značilne za obsevanje
• The active substance is cetuximab. 
• Učinkovina je cetuksimab.
Cetuximab plus OxMdG 
OxMdG Cetuximab in OxMdG
• blood clots in the veins of the legs 
• krvni strdki v venah na nogah
Treatment in the cetuximab arm consisted of up to 6 cycles of platinum-based chemotherapy in combination with cetuximab followed by cetuximab as maintenance therapy until disease progression. 
V skupini, ki je prejemala cetuksimab, je zdravljenje zajemalo do 6 ciklov kemoterapije na osnovi platine v kombinaciji s cetuksimabom, čemur je sledila vzdrževalna terapija s cetuksimabom do napredovanja bolezni.
There is limited experience with single doses higher than 400 mg/m2 body surface area to date or weekly administrations of doses higher than 250 mg/m 2 body surface area. 
Izkušnje z uporabo enkratnih odmerkov nad 400 mg/m² telesne površine ali tedensko uporabo odmerkov, večjih od 250 mg/m² telesne površine, so omejeni.
• nail disorders, for example inflammation of the nail bed 
• bolezni nohtov, na primer vnetje podnohtja
The RAS mutant population consists of patients with known KRAS exon 2 mutations as well as additionally identified RAS mutations. 
Populacija z mutacijo RAS je sestavljena iz bolnikov z znanimi mutacijami KRAS (eksona 2) in z dodatno opredeljenimi mutacijami RAS.
Results from clinical studies show a negative benefit-risk balance in tumours with RAS mutations. 
Rezultati kliničnih študij pri tumorjih z mutacijo RAS kažejo negativno razmerje med tveganjem in koristjo.
In patients with recurrent and/or metastatic squamous cell cancer of the head and neck, cetuximab is used in combination with platinum-based chemotherapy followed by cetuximab as maintenance therapy until disease progression (see section 5.1). 
Pri bolnikih s ponavljajočim se in/ali metastatskim rakom skvamoznih celic glave in vratu se cetuksimab uporablja v kombinaciji s kemoterapijo na osnovi platine, čemur sledi vzdrževalna terapija s cetuksimabom do napredovanja bolezni (glejte poglavje 5.1).
The first dose (400 mg/m² body surface area) is infused over a period of approximately 2 hours with an infusion rate not faster than 5 mg/min. 
Prvi odmerek (400 mg/m² telesne površine) bolniku infundiramo približno 2 uri s hitrostjo infundiranja, ki ni hitrejša kot 5 mg/min.
Cetuximab in combination with chemotherapy 
Cetuksimab v kombinaciji s kemoterapijo
Similarly, the pharmacokinetics of irinotecan were unchanged when cetuximab was co-administered. 
Tudi farmakokinetika irinotekana je nespremenjena pri sočasni uporabi cetuksimaba.
In vivo cetuximab inhibits expression of angiogenic factors by tumour cells and causes a reduction in tumour neo-vascularisation and metastasis. 
In vivo cetuksimab zavira ekspresijo angiogenih faktorjev v tumorskih celicah in zmanjša nastajanje novih tumorskih žil in metastaz.
Draw up the required volume of Erbitux from a vial. 
Posesajte potrebni volumen zdravila Erbitux iz viale.
• decrease in blood levels of calcium 
• znižanje ravni kalcija v krvi
These side effects normally occur during the infusion, within 1 hour afterwards, or sometimes also after this period. 
Ti neželeni učinki se navadno pojavijo med infundiranjem, eno uro po njem, včasih pa tudi pozneje.
The duration of treatment may vary depending on your disease as well as from person to person and your doctor will therefore discuss with you how long you will receive Erbitux. 
Dolžina zdravljenja je odvisna od vaše bolezni in se razlikuje od posameznika do posameznika.
Chemotherapy must not be administered earlier than 1 hour after the end of the cetuximab infusion. 
Kemoterapije bolnik ne sme prejeti prej kot 1 uro po koncu infuzije cetuksimaba.
Medium to high-potency topical corticosteroids or oral tetracyclines have been used for the treatment of skin reactions. 
Za zdravljenje kožnih reakcij so uporabili srednje do zelo močne topikalne kortikosteroide ali peroralne tetracikline.
All of these pathways involve the biodegradation of the antibody to smaller molecules, i.e. small peptides or amino acids. 
V vseh teh poteh pride do biološke razgradnje protiteles na manjše molekule, t.j.
Side effects concerning the lungs 
Neželeni učinki, povezani s pljuči
Cetuximab also targets cytotoxic immune effector cells towards EGFRexpressing tumour cells (antibody dependent cell-mediated cytotoxicity, ADCC). 
Cetuksimab tudi usmeri citotoksične imunske efektorske celice proti tumorskim celicam z ekspresijo EGFR (od protiteles odvisna celično posredovana citotoksičnost, POCC).
Erbitux 5 mg/mL is compatible 
Zdravilo Erbitux 5 mg/ml je združljivo
QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of solution for infusion contains 5 mg cetuximab. 
KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml raztopine za infundiranje vsebuje 5 mg cetuksimaba.
Overall, measurable HACA titres were noted in 3.4% of the patients studied, with incidences ranging from 0% to 9.6% in the target indication studies. 
Pri skupaj 3,4 % bolnikov, vključenih v študije, so opažali merljive titre HAHP - incidenca je bila od 0% do 9,6% v študijah ciljanih indikacij, vendar dokončnih podatkov o nevtralizaciji cetuksimaba s protitelesi HAHP še ni.
• The other ingredients are sodium chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide and water for injections. 
• Druge sestavine zdravila so natrijev klorid, glicin, polisorbat 80, citronska kislina monohidrat, natrijev hidroksid in voda za injekcije.
Sufficient data from pregnant or lactating women are not available. 
Ni zadostnih podatkov o uporabi cetuksimaba pri nosečnicah ali doječih materah.
Frequency not known (cannot be estimated from the available data) An asterisk (*) indicates that additional information on the respective undesirable effect is provided below the table. 
Zvezdica (*) označuje, da so dodatne informacije o zadevnem neželenem učinku podane pod spodnjo preglednico.
• with polyethylene (PE), polyurethane (PUR), ethyl vinyl acetate (EVA), polyolefine thermoplastic (TP) or polyvinyl chloride (PVC) infusion sets, 
• s polietilenskimi (PE), poliuretanskimi (PUR), etilvinilacetatnimi (EVA), poliolefinskimi termoplastičnimi (TP) ali polivinilkloridnimi (PVC) infuzijskimi sistemi,
No new safety signals were identified in paediatric patients as reported from a phase-I study. 
V študiji faze I niso poročali o novih signalih glede varnosti pri pediatričnih bolnikih.
Erbitux contains cetuximab, a monoclonal antibody. 
Zdravilo Erbitux vsebuje cetuksimab, monoklonsko protitelo.
If you receive Erbitux in combination with other anticancer medicines, including fluoropyrimidines, it may be more likely that you experience heart problems which may be life-threatening. 
Če prejmete zdravilo Erbitux v kombinaciji z drugimi zdravili proti raku, vključno s fluoropirimidini, je morda večja verjetnost za težave s srcem, ki lahko tudi ogrožajo vaše življenje.
Sodium chloride, glycine, polysorbate 80, citric acid monohydrate, sodium hydroxide, water for injections 
Natrijev klorid, glicin, polisorbat 80, citronska kislina monohidrat, natrijev hidroksid, voda za injekcije
• For administration with infusion pump or gravity drip (diluted with sterile sodium chloride 9 mg/mL (0.9%) solution): Take an infusion bag of adequate size of sterile sodium chloride 9 mg/mL (0.9%) solution. 
• Za uporabo z infuzijsko črpalko ali s težnostno kapalno infuzijo (razredčeno s sterilno raztopino natrijevega klorida 9 mg/ml (0,9%)): Vzemite vrečko za infundiranje primerne velikosti s sterilno raztopino natrijevega klorida 9 mg/ml (0,9%).
Chemical and physical in-use stability of Erbitux 5 mg/mL has been demonstrated for 48 hours at 25ºC, if the solution is prepared as described in section 6.6. 
Med uporabo je zdravilo Erbitux 5 mg/ml kemično in fizikalno stabilno do 48 ur pri temperaturi 25 °C, če je raztopina pripravljena, kot je opisano v poglavju 6.6.
• with polyethylene (PE), ethyl vinyl acetate (EVA) or polyvinyl chloride (PVC) bags, 
• s polietilenskimi (PE), etilvinilacetatnimi (EVA) ali polivinilkloridnimi (PVC) vrečkami,
Cetuximab pharmacokinetics were studied when cetuximab was administered as monotherapy or in combination with concomitant chemotherapy or radiation therapy in clinical studies. 
Farmakokinetiko cetuksimaba so v kliničnih študijah raziskovali pri uporabi cetuksimaba v monoterapiji ali v kombinirani terapiji s sočasno kemoterapijo ali radioterapijo.
There are no data on the effect of cetuximab on human fertility. 
Podatkov o učinku cetuksimaba na plodnost pri ljudeh ni.
Side effects concerning the skin 
Neželeni učinki, povezani s kožo
In these patients, Erbitux is used in combination with radiation therapy or with other anticancer medicines. 
Pri teh bolnikih se zdravilo Erbitux uporablja v kombinaciji z obsevanjem ali z drugimi zdravili proti raku.
FIRE-3, an investigator-sponsored clinical phase-III study, compared the treatment of FOLFIRI in combination with either cetuximab or bevacizumab in the first-line treatment of patients with KRAS exon 2 wild-type mCRC. 
V klinični študiji 3. faze, FIRE-3, ki jo je sponzoriral raziskovalec, so primerjali zdravljenje s FOLFIRI v kombinaciji z bodisi cetuksimabom ali bevacizumabom kot primarno zdravljenje bolnikov z mCRC z nemutiranim tipom KRAS (eksona 2).